Chronic Myeloid Leukaemia (CML) is a clonal, myeloproliferative disease that develops
when a single, pluripotential, haemopoetic stem cell acquires the Philadelphia chromosome …

Imatinib is the current standard of care in the treatment of chronic myeloid leukemia (CML),
inducing durable responses and prolonged progression-free survival. However, plasma …

Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic
phase. We here describe the correlation of imatinib trough plasma concentrations (Cmins) …

Imatinib, a potent tyrosine kinase inhibitor, is effluxed from cells by the breast cancer
resistance protein (BCRP/ABCG2), yet published studies to date fail to demonstrate …

Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML).
However, whether it should be discontinued in patients who achieve sustained molecular …

Background: Correlation analyses have demonstrated that maintaining an adequate
imatinib (IM) trough concentration would be important for clinical response in patients with …

Calcium is universally required for cell growth and proliferation. Calmodulin is the main
intracellular receptor for calcium. Although calcium and calmodulin are well known to be …

Imatinib is approved as a first-line treatment for Philadelphia chromosome-positive chronic
myeloid leukemia (CML). Because of the variability in imatinib exposure among patients …

Objective: To evaluate the response of imatinib mesylate in chronic phase of chronic
myeloid leukemia and to observe the significance of Sokal score and various factors which …

Chronic myeloid leukemia (CML) is the prototype cytogenetic malignancy. Even before the
development of basic G-banding techniques, CML was found to be associated with a …